Humacyte (HUMA) Net Margin (2020 - 2026)
Humacyte (HUMA) reported Net Margin of 6237.58% for Q1 2026, down 129792.0% year-over-year from N/an in Q1 2025, and up 12.85% quarter-over-quarter from 7157.6% in Q4 2025.
Humacyte (HUMA) Net Margin (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has 4 years of Net Margin data on file, last reported at 6237.58% in Q1 2026.
- Net Margin for Q1 2026 came in at 6237.58%, down 129792.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 6059.23% (up 1671795.0% YoY), and the FY2025 annual result was 5731.11%, changed N/A from the prior year.
- Net Margin climbed to 6237.58% in Q1 2026 per HUMA's latest filing, from 7157.6% in the prior quarter.
- Over five years, Net Margin peaked at 3507.57% in Q3 2025 and troughed at 10445.18% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Humacyte | 183.21 Mn | 134.67 Mn | -1.54 Mn | -6,237.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6,237.58% |
| Dec 31, 2025 | -7,157.60% |
| Sep 30, 2025 | -3,507.57% |
| Jun 30, 2025 | -10,445.18% |
| Mar 31, 2025 | -4,939.65% |
| Sep 30, 2021 | -9,022.41% |
| Sep 30, 2020 | -1,943.11% |